These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 31511498)

  • 41. MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11.
    Bockhorn J; Dalton R; Nwachukwu C; Huang S; Prat A; Yee K; Chang YF; Huo D; Wen Y; Swanson KE; Qiu T; Lu J; Park SY; Dolan ME; Perou CM; Olopade OI; Clarke MF; Greene GL; Liu H
    Nat Commun; 2013; 4():1393. PubMed ID: 23340433
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells.
    Zhong S; Li W; Chen Z; Xu J; Zhao J
    Gene; 2013 Nov; 531(1):8-14. PubMed ID: 23994196
    [TBL] [Abstract][Full Text] [Related]  

  • 43. RNAi-mediated knockdown of FANCF suppresses cell proliferation, migration, invasion, and drug resistance potential of breast cancer cells.
    Zhao L; Li N; Yu JK; Tang HT; Li YL; He M; Yu ZJ; Bai XF; Zheng ZH; Wang EH; Wei MJ
    Braz J Med Biol Res; 2014 Jan; 47(1):24-34. PubMed ID: 24345874
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The function role of miR-181a in chemosensitivity to adriamycin by targeting Bcl-2 in low-invasive breast cancer cells.
    Zhu Y; Wu J; Li S; Ma R; Cao H; Ji M; Jing C; Tang J
    Cell Physiol Biochem; 2013; 32(5):1225-37. PubMed ID: 24335172
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells.
    Ogretmen B; Safa AR
    Oncogene; 1997 Jan; 14(4):499-506. PubMed ID: 9053847
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gain-of-function p53 mutant with 21-bp deletion confers susceptibility to multidrug resistance in MCF-7 cells.
    Tsou SH; Hou MH; Hsu LC; Chen TM; Chen YH
    Int J Mol Med; 2016 Jan; 37(1):233-42. PubMed ID: 26572087
    [TBL] [Abstract][Full Text] [Related]  

  • 47. miR-222 confers the resistance of breast cancer cells to Adriamycin through suppression of p27(kip1) expression.
    Wang DD; Li J; Sha HH; Chen X; Yang SJ; Shen HY; Zhong SL; Zhao JH; Tang JH
    Gene; 2016 Sep; 590(1):44-50. PubMed ID: 27282281
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 7-O-geranylquercetin contributes to reverse P-gp-mediated adriamycin resistance in breast cancer.
    Zhang E; Liu J; Shi L; Guo X; Liang Z; Zuo J; Xu H; Wang H; Shu X; Huang S; Zhang S; Kang X; Zhen Y
    Life Sci; 2019 Dec; 238():116938. PubMed ID: 31593704
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Correction: Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response.
    Lin S; Yu L; Song X; Bi J; Jiang L; Wang Y; He M; Xiao Q; Sun M; Olopade OI; Zhao L; Wei M
    Cell Death Dis; 2022 Jan; 13(1):82. PubMed ID: 35078992
    [No Abstract]   [Full Text] [Related]  

  • 50. Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.
    Berge EO; Huun J; Lillehaug JR; Lønning PE; Knappskog S
    Biochim Biophys Acta; 2013 Mar; 1830(3):2790-7. PubMed ID: 23246812
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Downregulated miR‑130a enhances the sensitivity of acute myeloid leukemia cells to Adriamycin.
    Liu H; Liu M; Zhang J; Liang Y
    Mol Med Rep; 2020 Oct; 22(4):2810-2816. PubMed ID: 32945422
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors.
    Faversani A; Vaira V; Moro GP; Tosi D; Lopergolo A; Schultz DC; Rivadeneira D; Altieri DC; Bosari S
    Breast Cancer Res; 2014 May; 16(3):R55. PubMed ID: 24886669
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MicroRNA-30c-regulated HDAC9 mediates chemoresistance of breast cancer.
    Liang Z; Feng A; Shim H
    Cancer Chemother Pharmacol; 2020 Feb; 85(2):413-423. PubMed ID: 31907648
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MicroRNA-574 enhances doxorubicin resistance through down-regulating SMAD4 in breast cancer cells.
    Sun FD; Wang PC; Luan RL; Zou SH; Du X
    Eur Rev Med Pharmacol Sci; 2018 Mar; 22(5):1342-1350. PubMed ID: 29565492
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Protein arginine methyltransferase 1 may be involved in pregnane x receptor-activated overexpression of multidrug resistance 1 gene during acquired multidrug resistant.
    Li T; Kong AN; Ma Z; Liu H; Liu P; Xiao Y; Jiang X; Wang L
    Oncotarget; 2016 Apr; 7(15):20236-48. PubMed ID: 26934120
    [TBL] [Abstract][Full Text] [Related]  

  • 56. TUG1 confers Adriamycin resistance in acute myeloid leukemia by epigenetically suppressing miR-34a expression via EZH2.
    Li Q; Song W; Wang J
    Biomed Pharmacother; 2019 Jan; 109():1793-1801. PubMed ID: 30551433
    [TBL] [Abstract][Full Text] [Related]  

  • 57. miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer.
    Hu Y; Qiu Y; Yagüe E; Ji W; Liu J; Zhang J
    Cell Death Dis; 2016 Jun; 7(6):e2291. PubMed ID: 27362808
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Exosomes from adriamycin-resistant breast cancer cells transmit drug resistance partly by delivering miR-222.
    Yu DD; Wu Y; Zhang XH; Lv MM; Chen WX; Chen X; Yang SJ; Shen H; Zhong SL; Tang JH; Zhao JH
    Tumour Biol; 2016 Mar; 37(3):3227-35. PubMed ID: 26432333
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of Raf-1.
    Yang G; Wu D; Zhu J; Jiang O; Shi Q; Tian J; Weng Y
    Oncol Rep; 2013 Aug; 30(2):877-89. PubMed ID: 23760062
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Systematic expression analysis of genes related to multidrug-resistance in isogenic docetaxel- and adriamycin-resistant breast cancer cell lines.
    Li WJ; Zhong SL; Wu YJ; Xu WD; Xu JJ; Tang JH; Zhao JH
    Mol Biol Rep; 2013 Nov; 40(11):6143-50. PubMed ID: 24078162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.